Meeting
2023 ASCO Genitourinary Cancers Symposium
5-Year result of single-institute cohort study in single-fraction HDR monotherapy for localised prostate cancer.
Authors
Imtiaz Ahmed
Southend NHS Trust, Southend, United Kingdom
Imtiaz Ahmed , Khin Sandar Tun , Sharon Shibuthomas , Alex Cain , Sadia Mahar , Nicola Yoganayagam , Abby Cyriac , Mahbuba Choudhury , Daben Dawam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 362)
DOI
10.1200/JCO.2023.41.6_suppl.362
Abstract #
362
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Pilot study of moderately-hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
First Author: Kiyonao Nakamura
Poster
2016 ASCO Annual Meeting
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
First Author: Bernard M. Dubray
Poster
2019 Genitourinary Cancers Symposium
Rectal toxicity results for patients treated with HDR brachytherapy as monotherapy versus dose-escalated external beam radiotherapy for localized prostate cancer.
First Author: Jacob Samuel Parzen
Poster
2017 Genitourinary Cancers Symposium
Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.
First Author: Laura D'alimonte